These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12429994)

  • 1. Differential pathomechanisms of epidermal necrolytic blistering diseases.
    Paquet P; Piérard GE
    Int J Mol Med; 2002 Dec; 10(6):695-9. PubMed ID: 12429994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular logic of pemphigus and impetigo: the desmoglein story.
    Amagai M
    Vet Dermatol; 2009 Oct; 20(5-6):308-12. PubMed ID: 20178466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced toxic epidermal necrolysis and pancytopenia: a puzzling association.
    Paquet P; Jacob E; Pirson J; Pierard GE
    Int J Mol Med; 2005 Jul; 16(1):29-33. PubMed ID: 15942674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis.
    Paquet P; Jacob E; Damas P; Pirson J; Piérard G
    Arch Dermatol Res; 2005 Dec; 297(6):266-73. PubMed ID: 16249890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Removal of amino-terminal extracellular domains of desmoglein 1 by staphylococcal exfoliative toxin is sufficient to initiate epidermal blister formation.
    Nishifuji K; Shimizu A; Ishiko A; Iwasaki T; Amagai M
    J Dermatol Sci; 2010 Sep; 59(3):184-91. PubMed ID: 20728315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keratinocyte injury in drug-induced toxic epidermal necrolysis: Simultaneous but distinct topographic expression of CD95R and calprotectin.
    Paquet P; Piérard GE
    Int J Mol Med; 2002 Aug; 10(2):145-7. PubMed ID: 12119549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staphylococcal exfoliative toxins: "molecular scissors" of bacteria that attack the cutaneous defense barrier in mammals.
    Nishifuji K; Sugai M; Amagai M
    J Dermatol Sci; 2008 Jan; 49(1):21-31. PubMed ID: 17582744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1.
    Amagai M; Matsuyoshi N; Wang ZH; Andl C; Stanley JR
    Nat Med; 2000 Nov; 6(11):1275-7. PubMed ID: 11062541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal interleukin-8 and its receptor CXCR2 in drug-induced toxic epidermal necrolysis.
    Paquet P; Ribbens C; Piérard GE
    Clin Exp Dermatol; 2007 Nov; 32(6):728-32. PubMed ID: 17714530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining the pathogenic involvement of desmoglein 4 in pemphigus and staphylococcal scalded skin syndrome.
    Nagasaka T; Nishifuji K; Ota T; Whittock NV; Amagai M
    J Clin Invest; 2004 Nov; 114(10):1484-92. PubMed ID: 15545999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lyell syndrome revisited: analysis of 18 cases of severe bullous skin disease in a burns unit.
    Neff P; Meuli-Simmen C; Kempf W; Gaspert T; Meyer VE; Künzi W
    Br J Plast Surg; 2005 Jan; 58(1):73-80. PubMed ID: 15629170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Staphylococcal scalded skin syndrome in an adult with Hodgkin's disease.
    Ridgway HB; Lowe NJ
    Arch Dermatol; 1979 May; 115(5):589-90. PubMed ID: 443834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome.
    Stanley JR; Amagai M
    N Engl J Med; 2006 Oct; 355(17):1800-10. PubMed ID: 17065642
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immunological investigations on pathogenesis of staphylococcal scalded skin syndrome].
    Machida K
    Rinsho Byori; 1995 Jun; 43(6):547-56. PubMed ID: 7602798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial cell apoptosis in severe drug-induced bullous eruptions.
    Verneuil L; Ratajczak P; Allabert C; Leboeuf C; Comoz F; Janin A; Ameisen JC
    Br J Dermatol; 2009 Dec; 161(6):1371-5. PubMed ID: 19575754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case report of differentiating staphylococcal scalded skin syndrome and toxic epidermal necrolysis by optical coherence tomography.
    Hussain AA; Banzhaf CA; Themstrup L; Nielsen PL; Jemec GB
    Skin Res Technol; 2015 Aug; 21(3):363-5. PubMed ID: 25580955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staphylococcal scalded skin syndrome: loss of desmoglein 1 in patient skin.
    Aalfs AS; Oktarina DA; Diercks GF; Jonkman MF; Pas HH
    Eur J Dermatol; 2010; 20(4):451-6. PubMed ID: 20558334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of staphylococcal scalded skin syndrome.
    Patel GK
    Expert Rev Anti Infect Ther; 2004 Aug; 2(4):575-87. PubMed ID: 15482221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of blister formation by staphylococcal toxins.
    Hanakawa Y; Stanley JR
    J Biochem; 2004 Dec; 136(6):747-50. PubMed ID: 15671483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staphylococcal scalded skin syndrome: diagnosis and management.
    Patel GK; Finlay AY
    Am J Clin Dermatol; 2003; 4(3):165-75. PubMed ID: 12627992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.